Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 2/2014

01.05.2014 | short review

Treatment results and follow-up after definitive radio-chemotherapy in anal cancer: when to perform biopsies?

verfasst von: PD Dr. med. Martina Becker-Schiebe, Wolfgang Hoffmann

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten
share
TEILEN

Abstract

Management of anal cancer shifted from radical surgical procedures to sphincter-preserving approaches by combined radio-chemotherapy (RCT). Several randomized trials investigated the most appropriate chemotherapy schedule, radiation doses, and treatment techniques. RCT employing 5-fluorouracil (5-FU)/mitomycin C (MMC) remains the standard treatment. Cisplatin was proposed as an alternative drug but failed to improve outcome when given instead of MMC or during maintenance chemotherapy. Currently, studies are ongoing that investigate staging procedures like PET-CT and diagnostic workup processes in treatment follow-up.
This review focuses on treatment results of definitive RCT and factors related to treatment failure. Subsequent follow-up recommendations and the timing of invasive follow-up biopsies are discussed.
Literatur
1.
Zurück zum Zitat Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, Mitomycin and radiotherapy vs fl uorouracil, cisplatin and radiotherapy for carcinoma of the anal canal: a randomised controlled trial. JAMA. 2008;199:1914–21. CrossRef Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, Mitomycin and radiotherapy vs fl uorouracil, cisplatin and radiotherapy for carcinoma of the anal canal: a randomised controlled trial. JAMA. 2008;199:1914–21. CrossRef
2.
Zurück zum Zitat Ajani JA, Winter KA, Gunderson LL, et al. Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11). Cancer. 2010;116:4007–13. PubMedCrossRef Ajani JA, Winter KA, Gunderson LL, et al. Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11). Cancer. 2010;116:4007–13. PubMedCrossRef
3.
Zurück zum Zitat Ajani JA, Winter KA, Gunderson LL, et al. US intergroup anal carcinoma trial: tumor diameter predicts for colostomy. J Clin Oncol. 2009;27:1116–21. PubMedCentralPubMedCrossRef Ajani JA, Winter KA, Gunderson LL, et al. US intergroup anal carcinoma trial: tumor diameter predicts for colostomy. J Clin Oncol. 2009;27:1116–21. PubMedCentralPubMedCrossRef
4.
Zurück zum Zitat Allal A, Laurencet F, Reymond M, et al. Effectiveness of surgical salvage therapy of for patients with locally uncontrolled anal cancer after sphincter conserving treatment. Cancer. 1999;86:405–9. PubMedCrossRef Allal A, Laurencet F, Reymond M, et al. Effectiveness of surgical salvage therapy of for patients with locally uncontrolled anal cancer after sphincter conserving treatment. Cancer. 1999;86:405–9. PubMedCrossRef
5.
Zurück zum Zitat Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol. 1997;15:2040–9. PubMed Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol. 1997;15:2040–9. PubMed
6.
Zurück zum Zitat Chapet O, Gerard JP, Riche B, et al. Prognostic value of tumor regression evaluated after first course of radiotherapy for anal canal cancer. Int J Radiat Oncol Biol Phys. 2005;63(5):1316–24. PubMedCrossRef Chapet O, Gerard JP, Riche B, et al. Prognostic value of tumor regression evaluated after first course of radiotherapy for anal canal cancer. Int J Radiat Oncol Biol Phys. 2005;63(5):1316–24. PubMedCrossRef
7.
Zurück zum Zitat Chen Y, Yen S, Chen S, et al. Anus-preservation treatment for anal cancer: retrospective analysis at a single institution. J Surg Oncol. 2007;96:374–80. PubMedCrossRef Chen Y, Yen S, Chen S, et al. Anus-preservation treatment for anal cancer: retrospective analysis at a single institution. J Surg Oncol. 2007;96:374–80. PubMedCrossRef
8.
Zurück zum Zitat Cummings B, Keane T, O’Sullivan M, et al. Epidermoid anal cancer: treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C. Int J Radiat Oncol Biol Phys. 1991;21(5):1115–25. PubMedCrossRef Cummings B, Keane T, O’Sullivan M, et al. Epidermoid anal cancer: treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C. Int J Radiat Oncol Biol Phys. 1991;21(5):1115–25. PubMedCrossRef
9.
Zurück zum Zitat Cummings BJ, Brierley JD. Anal cancer. In: Halperin EC, Perez CA, Brady LW, editors. Principles and practice of radiation oncology. 5th ed. Philadelphia:Lippincott Williams & Wilkins; 2008. pp. 1383–96. Cummings BJ, Brierley JD. Anal cancer. In: Halperin EC, Perez CA, Brady LW, editors. Principles and practice of radiation oncology. 5th ed. Philadelphia:Lippincott Williams & Wilkins; 2008. pp. 1383–96.
10.
Zurück zum Zitat Ferrigno R, Nakamura RA, Dos Santos Novaes PE, et al. Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness. Int J Radiat Oncol Biol Phys. 2005;61:1136–42. PubMedCrossRef Ferrigno R, Nakamura RA, Dos Santos Novaes PE, et al. Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness. Int J Radiat Oncol Biol Phys. 2005;61:1136–42. PubMedCrossRef
11.
Zurück zum Zitat Flam M, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol. 1996;14:2527–39. PubMed Flam M, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol. 1996;14:2527–39. PubMed
12.
Zurück zum Zitat Glynne-Jones R, James R, Meadows H, et al. Optimum time to assess complete clinical response following chemoradiation using mitomycin or cisplatin with with or without maintenance cisplatin and 5 –fluorouracil in squamous cell carcinoma of the anus: Results of ACT II. J Clin Oncol. 2012;30:Suppl abst. 4004. Glynne-Jones R, James R, Meadows H, et al. Optimum time to assess complete clinical response following chemoradiation using mitomycin or cisplatin with with or without maintenance cisplatin and 5 –fluorouracil in squamous cell carcinoma of the anus: Results of ACT II. J Clin Oncol. 2012;30:Suppl abst. 4004.
13.
Zurück zum Zitat Glynne-Jones R, Northover J, Oliveira J. Anal cancer ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20(Suppl. 4):iv57–60. Glynne-Jones R, Northover J, Oliveira J. Anal cancer ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20(Suppl. 4):iv57–60.
14.
Zurück zum Zitat Gunderson L, Moughan J, Ajani J, et al. Anal carcinoma: impact of TN category of disease on survival, disease replapse, and colostomy failure in US GI RTOG 98-11 phase 3 trial. Int J Radiat Oncol Biol Phys. 2013;87:638–45. PubMedCrossRef Gunderson L, Moughan J, Ajani J, et al. Anal carcinoma: impact of TN category of disease on survival, disease replapse, and colostomy failure in US GI RTOG 98-11 phase 3 trial. Int J Radiat Oncol Biol Phys. 2013;87:638–45. PubMedCrossRef
15.
Zurück zum Zitat Gunderson LL, Winter KA, Ajani JA, et al. Long-term update of U.S. GI Intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluoruracil/cisplatin. J Clin Oncol. 2012;30:4344–51. PubMedCentralPubMedCrossRef Gunderson LL, Winter KA, Ajani JA, et al. Long-term update of U.S. GI Intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluoruracil/cisplatin. J Clin Oncol. 2012;30:4344–51. PubMedCentralPubMedCrossRef
16.
Zurück zum Zitat Hughes L, Rich T, Delclos L, et al. Radiotherapy for anal cancer: experience from 1979-1978. Int J Radiat Oncol Biol Phys. 1989;17:1153–60. Hughes L, Rich T, Delclos L, et al. Radiotherapy for anal cancer: experience from 1979-1978. Int J Radiat Oncol Biol Phys. 1989;17:1153–60.
17.
Zurück zum Zitat James R, Glynne-Jones R, Meadows H, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. Lancet Oncol. 2013;14:516–24. PubMedCrossRef James R, Glynne-Jones R, Meadows H, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. Lancet Oncol. 2013;14:516–24. PubMedCrossRef
18.
Zurück zum Zitat Johnson LG, Madeleine MM, Newcomer LM, et al. Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973–2000. Cancer. 2004;101:281–8. PubMedCrossRef Johnson LG, Madeleine MM, Newcomer LM, et al. Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973–2000. Cancer. 2004;101:281–8. PubMedCrossRef
19.
Zurück zum Zitat Mai S, Welzel G, Hermann B, et al. Can the radiation dose to CT enlarged but FDG PET negative inguinal lymph nodes in anal cancer be reduced? Strahlenther Onkol. 2009;4:1–6. Mai S, Welzel G, Hermann B, et al. Can the radiation dose to CT enlarged but FDG PET negative inguinal lymph nodes in anal cancer be reduced? Strahlenther Onkol. 2009;4:1–6.
21.
Zurück zum Zitat Nigro DN. Seydel HF, Facr MS, et al. Combined preoperative radiation and chemotherapy for squamous cell carcinoma ofthe anal canal. Cancer. 1983;51:1826–9. PubMedCrossRef Nigro DN. Seydel HF, Facr MS, et al. Combined preoperative radiation and chemotherapy for squamous cell carcinoma ofthe anal canal. Cancer. 1983;51:1826–9. PubMedCrossRef
22.
Zurück zum Zitat Northover J, Glynne-Jones R, Sebag-Montefi ore D, et al. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer. 2010;102:1123–8. PubMedCentralPubMedCrossRef Northover J, Glynne-Jones R, Sebag-Montefi ore D, et al. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer. 2010;102:1123–8. PubMedCentralPubMedCrossRef
23.
Zurück zum Zitat Rousseau DL, Thomas CR, Petrelli NJ, Kahlenberg MS. Sqamous cell carcinoma of the anal canal. Surg Oncol. 2005;14:121–32. PubMedCrossRef Rousseau DL, Thomas CR, Petrelli NJ, Kahlenberg MS. Sqamous cell carcinoma of the anal canal. Surg Oncol. 2005;14:121–32. PubMedCrossRef
24.
Zurück zum Zitat Sato H, Koh PK, Bartolo DCC. Management of anal canal cancer. Dis Colon Rectum. 2005;48:1301–15. PubMedCrossRef Sato H, Koh PK, Bartolo DCC. Management of anal canal cancer. Dis Colon Rectum. 2005;48:1301–15. PubMedCrossRef
25.
Zurück zum Zitat Schiebe M, Hoffmann W, Belka C, Schnauder M, Bamberg M. Mitomycin C related hemolytic uremic syndrome in cancer patients. Anticancer Drugs. 1998;9:433–35. PubMedCrossRef Schiebe M, Hoffmann W, Belka C, Schnauder M, Bamberg M. Mitomycin C related hemolytic uremic syndrome in cancer patients. Anticancer Drugs. 1998;9:433–35. PubMedCrossRef
26.
Zurück zum Zitat Schiller DE, Cummings BJ, Rai S, Le LW, Last L, Davey P, et al. Outcomes of salvage surgery for squamous cell carcinoma of the anal canal. Ann Surg Oncol. 2007;14:2780–9. PubMedCrossRef Schiller DE, Cummings BJ, Rai S, Le LW, Last L, Davey P, et al. Outcomes of salvage surgery for squamous cell carcinoma of the anal canal. Ann Surg Oncol. 2007;14:2780–9. PubMedCrossRef
27.
Zurück zum Zitat Schwarz J, Siegel B, Dehdashti F, et al. Tumor response and survival predicted by the post-therapy FDG-PET/CT in anal cancer. Int J Radiat Oncol Biol Phys. 2008;71:180–6. PubMedCrossRef Schwarz J, Siegel B, Dehdashti F, et al. Tumor response and survival predicted by the post-therapy FDG-PET/CT in anal cancer. Int J Radiat Oncol Biol Phys. 2008;71:180–6. PubMedCrossRef
Metadaten
Titel
Treatment results and follow-up after definitive radio-chemotherapy in anal cancer: when to perform biopsies?
verfasst von
PD Dr. med. Martina Becker-Schiebe
Wolfgang Hoffmann
Publikationsdatum
01.05.2014
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2014
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-014-0139-7